JP2022191301A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022191301A5 JP2022191301A5 JP2022155470A JP2022155470A JP2022191301A5 JP 2022191301 A5 JP2022191301 A5 JP 2022191301A5 JP 2022155470 A JP2022155470 A JP 2022155470A JP 2022155470 A JP2022155470 A JP 2022155470A JP 2022191301 A5 JP2022191301 A5 JP 2022191301A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- multiple myeloma
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023184430A JP7754906B2 (ja) | 2017-08-01 | 2023-10-27 | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539825P | 2017-08-01 | 2017-08-01 | |
| US62/539,825 | 2017-08-01 | ||
| US201762596194P | 2017-12-08 | 2017-12-08 | |
| US62/596,194 | 2017-12-08 | ||
| PCT/IB2018/055753 WO2019025983A1 (en) | 2017-08-01 | 2018-07-31 | CONJUGATED MONOCLONAL ANTIBODY-MEDICINE DIRECTED AGAINST BCMA |
| JP2020505483A JP7150820B2 (ja) | 2017-08-01 | 2018-07-31 | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505483A Division JP7150820B2 (ja) | 2017-08-01 | 2018-07-31 | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023184430A Division JP7754906B2 (ja) | 2017-08-01 | 2023-10-27 | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022191301A JP2022191301A (ja) | 2022-12-27 |
| JP2022191301A5 true JP2022191301A5 (https=) | 2023-05-29 |
| JP7377327B2 JP7377327B2 (ja) | 2023-11-09 |
Family
ID=63405281
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505483A Active JP7150820B2 (ja) | 2017-08-01 | 2018-07-31 | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
| JP2022155470A Active JP7377327B2 (ja) | 2017-08-01 | 2022-09-28 | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
| JP2023184430A Active JP7754906B2 (ja) | 2017-08-01 | 2023-10-27 | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505483A Active JP7150820B2 (ja) | 2017-08-01 | 2018-07-31 | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023184430A Active JP7754906B2 (ja) | 2017-08-01 | 2023-10-27 | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10988546B2 (https=) |
| EP (1) | EP3661963A1 (https=) |
| JP (3) | JP7150820B2 (https=) |
| KR (2) | KR102748628B1 (https=) |
| CN (2) | CN117018219A (https=) |
| AU (4) | AU2018311503C1 (https=) |
| BR (1) | BR112020001989A2 (https=) |
| CA (1) | CA3070539A1 (https=) |
| CL (1) | CL2020000263A1 (https=) |
| CO (1) | CO2020000772A2 (https=) |
| CR (1) | CR20200100A (https=) |
| EC (1) | ECSP20014523A (https=) |
| IL (2) | IL312451A (https=) |
| MA (1) | MA51447A (https=) |
| MX (1) | MX2025001287A (https=) |
| MY (1) | MY203183A (https=) |
| PH (1) | PH12020500177A1 (https=) |
| SG (1) | SG11202000499RA (https=) |
| TW (2) | TWI881438B (https=) |
| UA (1) | UA126813C2 (https=) |
| WO (1) | WO2019025983A1 (https=) |
| ZA (2) | ZA202001219B (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6685924B2 (ja) * | 2014-04-11 | 2020-04-22 | メディミューン，エルエルシー | システイン操作抗体を含むコンジュゲート化合物 |
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| EP3493844A4 (en) | 2016-05-20 | 2021-03-24 | Harpoon Therapeutics Inc. | SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| EP3621994A4 (en) | 2017-05-12 | 2020-12-30 | Harpoon Therapeutics, Inc. | MESOTHELIN BINDING PROTEINS |
| MA51447A (fr) * | 2017-08-01 | 2020-06-10 | Medimmune Llc | Conjugué anticorps monoclonal-médicament dirigé contre bcma |
| MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| MD3823665T2 (ro) | 2018-07-19 | 2024-05-31 | Regeneron Pharma | Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| KR20210133261A (ko) * | 2019-02-26 | 2021-11-05 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Bcma에 결합하는 항원 결합 단백질 |
| CA3132587A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| JP2022531001A (ja) * | 2019-05-03 | 2022-07-05 | セルジーン コーポレーション | 抗ｂｃｍａ抗体コンジュゲート、そのコンジュゲートを含む組成物ならびにそのコンジュゲートの製造および使用方法 |
| WO2020227105A1 (en) * | 2019-05-03 | 2020-11-12 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
| KR20220024106A (ko) * | 2019-05-20 | 2022-03-03 | 노파르티스 아게 | Mcl-1 억제제 항체-약물 접합체 및 사용 방법 |
| SG11202113008YA (en) * | 2019-05-31 | 2021-12-30 | Medimmune Llc | Combination therapy |
| MX2022001065A (es) * | 2019-07-30 | 2022-02-14 | Shanghai Hansoh Biomedical Co Ltd | Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo. |
| CN112409482B (zh) * | 2019-08-20 | 2022-08-26 | 杭州尚健生物技术有限公司 | Bcma抗体 |
| WO2021190564A1 (zh) * | 2020-03-26 | 2021-09-30 | 上海翰森生物医药科技有限公司 | 抗体药物偶联物及其医药用途 |
| CN113637073B (zh) * | 2020-05-11 | 2024-04-12 | 上海赛比曼生物科技有限公司 | Bcma抗体及其制备和应用 |
| AU2021284401A1 (en) * | 2020-06-05 | 2023-01-05 | Eisai R&D Management Co., Ltd. | Anti-BCMA antibody-drug conjugates and methods of use |
| CN112285361B (zh) * | 2020-09-27 | 2023-12-05 | 中国人民解放军空军军医大学 | 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂 |
| WO2022097047A1 (en) * | 2020-11-04 | 2022-05-12 | Medimmune, Llc | Treatment methods using anti-bcma antibody-drug conjugates |
| CN114763383B (zh) * | 2021-01-13 | 2024-12-17 | 博生吉医药科技(苏州)有限公司 | 靶向人bcma的单克隆抗体及其应用 |
| CN112812185B (zh) * | 2021-02-08 | 2022-01-18 | 华道(上海)生物医药有限公司 | 一种抗b细胞成熟抗原的单克隆抗体及其应用 |
| US20240181073A1 (en) * | 2021-03-03 | 2024-06-06 | Sorrento Therapeutics, Inc. | Antibody-Drug Conjugates Comprising an Anti-BCMA Antibody |
| WO2022232488A1 (en) | 2021-04-30 | 2022-11-03 | Celgene Corporation | Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamma secretase inhibitor (gsi) |
| WO2023019398A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Bcma targetting antibodies, chimeric antigen receptors, and uses thereof |
| EP4426727A2 (en) * | 2021-11-03 | 2024-09-11 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| CN117164714B (zh) * | 2023-10-08 | 2024-04-23 | 北京奇迈永华生物科技有限公司 | 一种靶向bcma的抗体及其应用 |
| US20250242018A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025160324A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| CN119841951B (zh) * | 2024-12-25 | 2025-10-14 | 厦门大学附属第一医院(厦门市第一医院、厦门市红十字会医院、厦门市糖尿病研究所) | 一种抗bcma抗体或其抗原结合片段及其制备方法和应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| JPS58180487A (ja) | 1982-04-16 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | 抗生物質ｄｃ−８１およびその製造法 |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US7776814B2 (en) | 2002-07-09 | 2010-08-17 | R&D-Biopharmaceuticals Gmbh | Tubulysin conjugates |
| DK1523493T3 (da) | 2002-07-09 | 2013-12-02 | Alexander Doemling | Nye tubulysinanaloge |
| DE10254439A1 (de) | 2002-11-21 | 2004-06-03 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Tubulysine, Herstellungsverfahren und Tubulysin-Mittel |
| US20090075378A1 (en) | 2007-02-20 | 2009-03-19 | Anaptysbio, Inc. | Somatic hypermutation systems |
| US8476451B2 (en) | 2007-07-20 | 2013-07-02 | The Regents Of The University Of California | Tubulysin D analogues |
| EP2181101A2 (en) | 2007-07-20 | 2010-05-05 | Helmholtz-Zentrum für Infektionsforschung GmbH | Tubulysin d analogues |
| CN101909441B (zh) | 2007-10-25 | 2015-05-13 | 恩多塞特公司 | 微管蛋白抑制剂及其制备方法 |
| MX341884B (es) | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
| JP2013535220A (ja) | 2010-08-06 | 2013-09-12 | エンドサイト，インコーポレイテッド | ツブリシンを調製するためのプロセス |
| KR101972446B1 (ko) * | 2011-05-27 | 2019-04-25 | 글락소 그룹 리미티드 | Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질 |
| UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
| RU2766608C2 (ru) * | 2012-04-11 | 2022-03-15 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
| MX338711B (es) | 2012-10-12 | 2016-04-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| US9243058B2 (en) * | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| SG11201608192SA (en) | 2014-04-11 | 2016-10-28 | Medimmune Llc | Bispecific her2 antibodies |
| WO2015155345A1 (en) | 2014-04-11 | 2015-10-15 | Medimmune Limited | Antibodies and antibody-drug conjugates |
| EA032203B1 (ru) | 2014-04-11 | 2019-04-30 | МЕДИММЬЮН ЭлЭлСи | Производные тубулизина |
| EP3209334A2 (en) * | 2014-10-20 | 2017-08-30 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions, and methods of use |
| TWI703159B (zh) * | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| MX2018002043A (es) * | 2015-08-17 | 2018-07-06 | Janssen Pharmaceutica Nv | ANTICUERPOS ANTI-BCMA, MOLíCULAS DE UNIíN A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS. |
| MA51447A (fr) * | 2017-08-01 | 2020-06-10 | Medimmune Llc | Conjugué anticorps monoclonal-médicament dirigé contre bcma |
| SG11202113008YA (en) * | 2019-05-31 | 2021-12-30 | Medimmune Llc | Combination therapy |
-
2018
- 2018-07-31 MA MA051447A patent/MA51447A/fr unknown
- 2018-07-31 CR CR20200100A patent/CR20200100A/es unknown
- 2018-07-31 CN CN202311040626.0A patent/CN117018219A/zh active Pending
- 2018-07-31 IL IL312451A patent/IL312451A/en unknown
- 2018-07-31 BR BR112020001989-5A patent/BR112020001989A2/pt unknown
- 2018-07-31 IL IL272304A patent/IL272304B2/en unknown
- 2018-07-31 TW TW112131870A patent/TWI881438B/zh active
- 2018-07-31 SG SG11202000499RA patent/SG11202000499RA/en unknown
- 2018-07-31 CA CA3070539A patent/CA3070539A1/en active Pending
- 2018-07-31 KR KR1020207005140A patent/KR102748628B1/ko active Active
- 2018-07-31 AU AU2018311503A patent/AU2018311503C1/en active Active
- 2018-07-31 CN CN201880049730.7A patent/CN110997721B/zh active Active
- 2018-07-31 TW TW107126542A patent/TWI815815B/zh active
- 2018-07-31 JP JP2020505483A patent/JP7150820B2/ja active Active
- 2018-07-31 MY MYPI2020000524A patent/MY203183A/en unknown
- 2018-07-31 US US16/050,944 patent/US10988546B2/en active Active
- 2018-07-31 EP EP18760047.3A patent/EP3661963A1/en active Pending
- 2018-07-31 KR KR1020247042931A patent/KR20250009550A/ko active Pending
- 2018-07-31 WO PCT/IB2018/055753 patent/WO2019025983A1/en not_active Ceased
- 2018-07-31 UA UAA202000974A patent/UA126813C2/uk unknown
-
2020
- 2020-01-23 CO CONC2020/0000772A patent/CO2020000772A2/es unknown
- 2020-01-24 PH PH12020500177A patent/PH12020500177A1/en unknown
- 2020-01-28 MX MX2025001287A patent/MX2025001287A/es unknown
- 2020-01-30 CL CL2020000263A patent/CL2020000263A1/es unknown
- 2020-02-26 ZA ZA2020/01219A patent/ZA202001219B/en unknown
- 2020-02-27 EC ECSENADI202014523A patent/ECSP20014523A/es unknown
-
2021
- 2021-03-29 US US17/215,479 patent/US11912782B2/en active Active
- 2021-08-25 ZA ZA2021/06131A patent/ZA202106131B/en unknown
-
2022
- 2022-03-01 AU AU2022201397A patent/AU2022201397B2/en active Active
- 2022-09-28 JP JP2022155470A patent/JP7377327B2/ja active Active
-
2023
- 2023-10-27 JP JP2023184430A patent/JP7754906B2/ja active Active
-
2024
- 2024-01-17 US US18/414,892 patent/US20240294666A1/en active Pending
- 2024-02-09 AU AU2024200847A patent/AU2024200847B2/en active Active
-
2025
- 2025-05-06 AU AU2025203224A patent/AU2025203224A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022191301A5 (https=) | ||
| RU2421464C2 (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
| JP2022177090A5 (https=) | ||
| JP2021527431A5 (https=) | ||
| JP2019532056A5 (https=) | ||
| JP2011502137A5 (https=) | ||
| JP2025131696A5 (https=) | ||
| JP2013542194A5 (https=) | ||
| JP2008529497A5 (https=) | ||
| JP2021527640A5 (https=) | ||
| IL273841B1 (en) | Antibodies targeting cd137 and methods of use thereof | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| NZ575245A (en) | Targeted binding agents directed to pdgfr-alpha and uses thereof | |
| JP2015503909A5 (https=) | ||
| JP2023055904A5 (https=) | ||
| JP2012532851A5 (https=) | ||
| FI3810281T3 (fi) | Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla | |
| JP2022533538A5 (https=) | ||
| RU2018120695A (ru) | Связывающие молекулы, специфичные в отношении asct2, и их применения | |
| JP2014524902A5 (https=) | ||
| JP2023093753A5 (https=) | ||
| JP2025501775A5 (https=) | ||
| JP2020522281A5 (https=) | ||
| JP2024546497A5 (https=) | ||
| JP2020522280A5 (https=) |